Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pritelivir - AiCuris

Next Previous
X
Search
Drug Profile

Pritelivir - AiCuris

Alternative Names: AIC-316; BAY 57-1293

Latest Information Update: 28 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer AiCuris
  • Class Amides; Antivirals; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action DNA helicase-primase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Herpes simplex virus infections
  • Phase II Herpes labialis; Herpes simplex virus type 2 infections

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Herpes-simplex-virus-infections in Germany (Vaginal, Ring)
  • 18 May 2023 AiCuris competes a phase-I clinical trials in Herpes simplex virus infections (In volunteers) in United Kingdom (PO) (NCT05671029)
  • 06 May 2023 AiCuris initiates enrolment in an expanded access programme for Herpes simplex virus infections (Treatment-resistant, In children, In Adults, In the elderly) in USA (PO) as of May 2023 (NCT05844436)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top